We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Day One Biopharmaceuticals Inc (DAWN) USD0.0001

Sell:$12.78 Buy:$12.80 Change: $0.46 (3.65%)
NASDAQ:1.03%
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$12.78
Buy:$12.80
Change: $0.46 (3.65%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$12.78
Buy:$12.80
Change: $0.46 (3.65%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.

Contact details

Address:
2000 Sierra Point Parkway, Suite 501
BRISBANE
94080-1930
United States
Telephone:
+1 (650) 4840899
Website:
https://dayonebio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DAWN
ISIN:
US23954D1090
Market cap:
$1.26 billion
Shares in issue:
100.85 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jeremy Bender
    President, Chief Executive Officer, Director
  • Samuel Blackman
    Co-Founder and Head of Research and Development
  • Charles York
    Chief Financial Officer, Chief Operating Officer, Secretary
  • Adam Dubow
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.